EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS), a leader in self injection drug delivery technology, today announced the receipt of a sales-based milestone from Teva. Antares’ novel delivery device, branded as Tjet® is used to deliver TEV-TROPIN® brand human growth hormone (hGH) to children who have growth failure due to inadequate secretion of normal endogenous growth hormone. The $0.5 million milestone was related to achieving an undisclosed sales volume of TEV-TROPIN®.
